You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 6, 2025

CLINICAL TRIALS PROFILE FOR MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00004399 ↗ Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia Completed University of Utah N/A 1995-09-01 OBJECTIVES: I. Determine the effectiveness of nimodipine versus magnesium sulfate in the prevention of eclamptic seizures in patients with severe preeclampsia.
NCT00004399 ↗ Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia Completed FDA Office of Orphan Products Development N/A 1995-09-01 OBJECTIVES: I. Determine the effectiveness of nimodipine versus magnesium sulfate in the prevention of eclamptic seizures in patients with severe preeclampsia.
NCT00002146 ↗ Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed Astra USA Phase 4 1969-12-31 To determine whether acute ionized hypomagnesemia and hypocalcemia immediately following foscarnet infusions can be lessened or eliminated by prior infusion of magnesium sulfate. To determine whether reductions in ionized magnesium, ionized calcium, and parathyroid hormone levels following foscarnet infusions are lessened by preinfusion of magnesium sulfate. To evaluate the safety of intravenous magnesium sulfate prior to foscarnet infusion by monitoring blood pressure, heart rate, and heart rhythm. To characterize the effect of magnesium sulfate on foscarnet blood levels and urinary excretion of calcium, magnesium, phosphate, and foscarnet.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 3 of 3 entries

Clinical Trial Conditions for MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Condition Name

2111110-20246810121416182022Postoperative PainPreeclampsiaMagnesium Sulfate[disabled in preview]
Condition Name for MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Intervention Trials
Postoperative Pain 21
Preeclampsia 11
Magnesium Sulfate 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

37261700510152025303540Pain, PostoperativePre-EclampsiaObstetric Labor, Premature[disabled in preview]
Condition MeSH for MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Intervention Trials
Pain, Postoperative 37
Pre-Eclampsia 26
Obstetric Labor, Premature 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Trials by Country

+
Trials by Country for MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Location Trials
United States 130
Egypt 84
Korea, Republic of 18
Brazil 17
Canada 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Location Trials
California 13
New York 9
Ohio 9
Pennsylvania 8
Illinois 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Clinical Trial Phase

55.4%29.1%15.5%00102030405060708090Phase 4Phase 3Phase 2/Phase 3[disabled in preview]
Clinical Trial Phase for MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase Trials
Phase 4 82
Phase 3 43
Phase 2/Phase 3 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

58.3%22.8%18.9%0020406080100120140160CompletedRecruitingNot yet recruiting[disabled in preview]
Clinical Trial Status for MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase Trials
Completed 148
Recruiting 58
Not yet recruiting 48
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Sponsor Name

trials05101520253035Assiut UniversityCairo UniversitySeoul National University Bundang Hospital[disabled in preview]
Sponsor Name for MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor Trials
Assiut University 33
Cairo University 17
Seoul National University Bundang Hospital 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

94.0%0050100150200250300350400OtherNIHIndustry[disabled in preview]
Sponsor Type for MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor Trials
Other 394
NIH 13
Industry 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Magnesium Sulfate in Dextrose 5%: Clinical Trials, Market Analysis, and Projections

Introduction

Magnesium Sulfate in Dextrose 5% is a crucial medication used in various medical applications, particularly in the treatment and prevention of eclampsia and preeclampsia. This article will delve into the current clinical trials, market analysis, and future projections for this drug.

Clinical Uses and Indications

Magnesium Sulfate in Dextrose 5% is primarily indicated for the prevention of eclampsia in patients with preeclampsia and the treatment of seizures and prevention of recurrent seizures in patients with eclampsia[1][3].

Dosage and Administration

The recommended loading dosage is 4 to 6 grams over 15 minutes, followed by a maintenance dosage of 1 to 2 grams every hour. It is essential to monitor serum magnesium concentrations and clinical signs of magnesium toxicity, such as respiratory depression and diminished deep tendon reflexes[1][3].

Clinical Trials

Ongoing and Recent Studies

Clinical trials continue to investigate the efficacy and safety of magnesium sulfate in various contexts. For example, a study registered on the Chinese Clinical Trial Register aims to investigate the effect of intravenous magnesium sulfate on the quality of early recovery after surgery. Such studies help in understanding the broader applications and optimal dosing regimens of magnesium sulfate[5].

Safety and Efficacy

Clinical trials emphasize the importance of monitoring for magnesium toxicity, which can include symptoms such as facial edema, diminished strength of deep tendon reflexes, and respiratory depression. The presence of the patellar reflex and the absence of respiratory depression are clinical indicators of a safe dosage regimen[1].

Market Analysis

Global Market Size and Growth

The global magnesium sulfate market is projected to grow significantly. In 2023, the market size was USD 980.4 million, and it is expected to grow to USD 1,583.9 million by 2032 at a CAGR of 5.5%[2].

Key Drivers of Market Growth

  • Agricultural Demand: The increasing demand from the agricultural industry, driven by the need to correct magnesium deficiencies in soil, is a major factor. Farmers rely on magnesium sulfate as a fertilizer to enhance crop growth[2].
  • Pharmaceutical Applications: The versatile nature of magnesium sulfate in treating eclampsia, preeclampsia, and other medical conditions contributes to its growing demand in the pharmaceutical sector[2].
  • Personal Care and Cosmetics: The rising trend of personal grooming and the demand for cosmetic products also fuel the market growth[2].

Regional Market Analysis

  • Asia Pacific: This region dominates the magnesium sulfate market, with countries like China, India, and Japan driving the growth due to extensive industrialization and urbanization[2].
  • North America and Europe: These regions also show significant growth, driven by factors such as increasing spending on personal care products, technological advancements in agriculture, and investments in healthcare infrastructure[2].

Market Projections

Future Growth Opportunities

The market is expected to continue growing due to several factors:

  • Sustainable Practices: The adoption of sustainable practices in agriculture and other industries will offer growth opportunities for key players in the magnesium sulfate market[2].
  • Increasing Population and Urbanization: The growing population and changing lifestyle in regions like the Middle East and Africa will surge the demand for magnesium sulfate in various applications[2].

Challenges and Restraints

Despite the growth potential, the market faces challenges such as:

  • Volatility in Prices: Fluctuations in energy prices and raw material costs affect the overall cost of magnesium sulfate, which can restrain market growth[2].
  • Adverse Health Effects: The potential adverse effects of magnesium compound-based drugs, such as hives, diarrhea, and difficulty in breathing, can also hamper market growth[2].

Dextrose Component Analysis

Role of Dextrose

The dextrose component in Magnesium Sulfate in Dextrose 5% serves as a source of energy and helps in maintaining hydration. However, it is crucial to use this solution with caution in patients with known prediabetes or diabetes mellitus due to the risk of elevated blood glucose[1].

Dextrose Market Trends

The global dextrose market is also growing, driven by the expansion of the food and beverage industry, the pharmaceutical sector, and increasing demand for convenience foods. The dextrose market is expected to grow from $5.8 billion in 2023 to $6.29 billion in 2024 at a CAGR of 8.5%[4].

Key Takeaways

  • Clinical Indications: Magnesium Sulfate in Dextrose 5% is primarily used for preventing eclampsia and treating seizures in preeclampsia and eclampsia.
  • Market Growth: The global magnesium sulfate market is projected to grow at a CAGR of 5.5% from 2024 to 2032.
  • Key Drivers: Agricultural demand, pharmaceutical applications, and personal care needs are driving the market growth.
  • Challenges: Volatility in prices and potential adverse health effects are significant restraints.
  • Dextrose Component: The dextrose in the solution is crucial but requires caution in patients with diabetes or prediabetes.

FAQs

What are the primary indications for Magnesium Sulfate in Dextrose 5%?

Magnesium Sulfate in Dextrose 5% is primarily indicated for the prevention of eclampsia in patients with preeclampsia and the treatment of seizures and prevention of recurrent seizures in patients with eclampsia.

What are the recommended dosages for Magnesium Sulfate in Dextrose 5%?

The recommended loading dosage is 4 to 6 grams over 15 minutes, followed by a maintenance dosage of 1 to 2 grams every hour.

What are the risks associated with Magnesium Sulfate in Dextrose 5%?

The risks include magnesium toxicity, which can lead to respiratory depression, acute renal failure, and pulmonary edema. There is also a risk of elevated blood glucose in patients with diabetes or prediabetes.

How is the global magnesium sulfate market projected to grow?

The global magnesium sulfate market is projected to grow from USD 1,034.0 million in 2024 to USD 1,583.9 million by 2032 at a CAGR of 5.5%.

What are the key drivers of the magnesium sulfate market growth?

The key drivers include increasing demand from the agricultural industry, growing pharmaceutical applications, and rising demand for personal care and cosmetic products.

Sources

  1. Drugs.com: Magnesium Sulfate in Dextrose Injection - Drugs.com
  2. Fortune Business Insights: Magnesium Sulfate Market Size, Share & Growth | Report [2032]
  3. Pfizer Medical Information: Magnesium Sulfate in 5% Dextrose Injection, USP Dosage and Administration
  4. The Business Research Company: Global Dextrose Market Report 2024
  5. Chinese Clinical Trial Register: Objectives of Study: The purpose of this study is to investigate the effect of intravenous magnesium sulfate on the quality of early recovery after surgery.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.